To help people experiencing the lingering effects of coronavirus infection, the Pulmonary Wellness Foundation (PWF) has launched a free online rehabilitation and recovery program called COVID Bootcamp 101. In addition to patient education and support, the program offers breathing and other exercises conducted by a team of…
Free Online ‘Bootcamp’ Aims to Help Those With Lingering COVID-19 Effects
The European Research Council (ERC) has awarded the Institute for Research in Biomedicine (IRB) Barcelona a €150,000 ($176,000) Proof of Concept grant to develop new medications to treat fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). The grant, which provides for 18 months of funding, also…
People with idiopathic pulmonary fibrosis (IPF) are at increased risk of several cancers other than lung cancer, a new study reports. The study, “Risk of cancer incidence in patients with idiopathic pulmonary fibrosis: A nationwide cohort study,” was published in the journal Respirology. IPF and…
Blocking an enzyme — called 15-PGDH — in a mouse model of pulmonary fibrosis (PF) limited early-stage inflammation and the development of fibrosis in the lungs, aiding the animals’ survival, a study demonstrated. These findings support further work targeting 15-PGDH as a…
Have you ever suddenly realized you are part of something special? This happened to me today during a video call with other members of the Bionews Insights (BNI) team. BNI is a relatively new division of our company, Bionews, focused on market research. The team is small, but this…
Conditions affecting the heart, stomach, and esophagus occur more frequently in patients whose diagnosis of idiopathic pulmonary fibrosis (IPF) is delayed, coming more than one year after the onset of symptoms, according to a recent study. This delayed diagnosis seems, however, to have no impact on the risk of…
A three-year pulmonary rehabilitation program — a combination of aerobic, resistance, and breathing exercises — helped to maintain lung and muscle strength before a double-lung transplant in a middle-aged man with idiopathic pulmonary fibrosis (IPF) and a sedentary lifestyle, a case study reports. The study “Long-Term…
Biognosys and Boehringer Ingelheim are working together to expand the use of cutting-edge technologies for large-scale protein analysis in drug discovery, beginning with a study of potential new treatment approaches to idiopathic pulmonary fibrosis (IPF). Biognosys announced that it will bring its expertise in proteomics — the…
Exposure to secondhand smoke, dust, or asbestos in the workplace is linked to a significantly higher risk of developing idiopathic pulmonary fibrosis (IPF), according to findings of an Australian study. These results suggest that “the burden of IPF could be reduced by intensified tobacco control, occupational dust control measures…
Two weeks after my mom, Holly’s, double-lung transplant, she was discharged from the hospital. Although she was weak, she was walking, talking, eating, and, best of all, breathing on her own. After three months on a ventilator, the transplant brought her back to life.
Your PF Community
Recommended Posts
- With FDA hold lifted, IPF clinical trial of LTI-03 begins dosing patients
- How we manage the long commute to my IPF doctor appointments
- In preparing for emergencies, we’re using technology to our advantage
- US, EU regulators name deupirfenidone an orphan drug for treating IPF
- This month is our time to raise awareness about rare diseases
